NCT04647916
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have at least 1 measurable brain metastasis greater than or equal to 1.0 cm in size that has not been irradiated; Patients must have had CNS progression after previous CNS-directed therapy (radiation therapy, surgery, or any combination of therapy)
Exclusions:
https://ClinicalTrials.gov/show/NCT04647916